Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington`s disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
Website: sana.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.13 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -64.8% (LTM)

Entry Point: Share price is 269.4% higher than minimum and 56.1% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: SANA
Share price, USD:  (-3.5%)4.95
year average price 3.16  


year start price 6.40 2024-07-27

max close price 6.40 2024-07-27

min close price 1.34 2025-04-08

current price 4.95 2025-07-26
Common stocks: 188 344 000

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 932
Net Debt ($m): -76
EV (Enterprise Value): 856
Price to Book: 3.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-20accessnewswire.com

Lost Money on Sana Biotechnology, Inc. (SANA)? Join Class Action Before May 20, 2025 - Contact Levi & Korsinsky

2025-05-20prnewswire.com

Levi & Korsinsky Notifies Shareholders of Sana Biotechnology, Inc.(SANA) of a Class Action Lawsuit and an Upcoming Deadline

2025-05-19accessnewswire.com

SANA LAWSUIT ALERT: Levi & Korsinsky Notifies Sana Biotechnology, Inc. Investors - Lead Plaintiff Deadline May 20, 2025

2025-05-19seekingalpha.com

Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment

2025-05-19accessnewswire.com

Class Action Filed Against Sana Biotechnology, Inc. (SANA) Over Securities Violations - Contact Levi & Korsinsky Today

2025-05-19globenewswire.com

SANA DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important May 20 Deadline in Securities Class Action – SANA

2025-05-19accessnewswire.com

Join Class Action to Recover Losses from Sana Biotechnology, Inc. (SANA) - Contact Levi & Korsinsky Before May 20, 2025

2025-05-18accessnewswire.com

Contact Levi & Korsinsky by May 20, 2025 to Join Class Action Against Sana Biotechnology, Inc. (SANA)

2025-05-18accessnewswire.com

SANA FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sana Biotechnology, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 20 Deadline in Securities Class Action - SANA

2025-05-18accessnewswire.com

Investors in Sana Biotechnology, Inc. (SANA): Protect Your Rights - Contact Levi & Korsinsky Before May 20, 2025
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SANA SANA SANA SANA SANA SANA SANA SANA SANA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-08 2024-08-08 2024-05-08 2023-12-31 2023-11-08 2023-08-03 2023-05-08 2023-03-16 2022-11-02
acceptedDate 2024-11-08 09:14:14 2024-08-08 16:21:48 2024-05-08 16:21:34 2023-12-30 19:00:00 2023-11-08 16:24:11 2023-08-03 16:23:19 2023-05-08 16:33:57 2023-03-16 16:25:20 2022-11-02 16:17:23
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 0 0 0 0 0 0 0 0
costOfRevenue 0 4M 4M 8M 4M 8M 0 0 0
grossProfit 0 -4M -4M -8M -4M -8M 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 48M 36M 89M 49M -17M 100M 67M 58M 71M
generalAndAdministrativeExpenses 14M 16M 16M 21M 19M 17M 17M 23M 16M
sellingAndMarketingExpenses 0 -4M -4M 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 14M 13M 13M 21M 19M 17M 17M 23M 16M
otherExpenses 0 -4M 215 000 -224 000 303 000 -84 000 -47 000 -268 000 0
operatingExpenses 62M 49M 102M 69M 2M 116M 84M 82M 86M
costAndExpenses 62M 53M 105M 77M 2M 116M 84M 82M 86M
interestIncome 3M 3M 3M 3M 3M 2M 2M 2M 1M
interestExpense 0 0 0 0 0 0 -2M -2M 1M
depreciationAndAmortization 4M 4M 4M 8M 4M 4M 4M 4M 4M
ebitda -58M -46M -102M -69M 2M -116M -84M -82M -82M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -62M -53M -105M -77M -2M -116M -84M -82M -86M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet 2M -919 000 -2M -11M 303 000 -84 000 2M 1M 1M
incomeBeforeTax -60M -50M -107M -88M 984 000 -114M -82M -80M -85M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 4M 7M -3M -7M -2M -2M -1M
netIncome -60M -50M -107M -88M 984 000 -114M -80M -78M -84M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -0.25 -0.21 -0.49 -0.45 0.005 -0.59 -0.42 -0.41 -0.44
epsdiluted -0.25 -0.21 -0.49 -0.45 0.005 -0.59 -0.42 -0.41 -0.44
weightedAverageShsOut 235M 234M 217M 197M 197M 193M 191M 190M 189M
weightedAverageShsOutDil 235M 234M 217M 197M 200M 193M 191M 190M 189M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SANA SANA SANA SANA SANA SANA SANA SANA SANA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-08 2024-08-08 2024-05-08 2023-12-31 2023-11-08 2023-08-03 2023-05-08 2023-03-16 2022-11-02
acceptedDate 2024-11-08 09:14:14 2024-08-08 16:21:48 2024-05-08 16:21:34 2023-12-30 19:00:00 2023-11-08 16:24:11 2023-08-03 16:23:19 2023-05-08 16:33:57 2023-03-16 16:25:20 2022-11-02 16:17:23
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 127M 139M 181M 137M 168M 174M 160M 177M 163M
shortTermInvestments 72M 117M 134M 72M 100M 152M 189M 247M 322M
cashAndShortTermInvestments 199M 255M 315M 209M 269M 326M 355M 434M 486M
netReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
otherCurrentAssets 11M 8M 6M 4M 7M 7M 15M 14M 15M
totalCurrentAssets 210M 263M 321M 214M 280M 339M 370M 444M 500M
propertyPlantEquipmentNet 144M 149M 153M 146M 146M 157M 162M 159M 163M
goodwill 141M 141M 141M 141M 141M 141M 141M 141M 141M
intangibleAssets 59M 59M 59M 59M 59M 59M 59M 59M 59M
goodwillAndIntangibleAssets 200M 200M 200M 200M 200M 200M 200M 200M 200M
longTermInvestments 0 0 0 0 0 4M 6M 10M 26M
taxAssets 0 0 0 0 0 -4M 0 0 0
otherNonCurrentAssets 6M 6M 7M 6M 6M 11M 9M 9M 9M
totalNonCurrentAssets 349M 355M 360M 352M 352M 369M 377M 378M 398M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 559M 619M 681M 565M 631M 707M 747M 823M 898M
accountPayables 3M 4M 6M 4M 10M 3M 2M 3M 4M
shortTermDebt 11M 20M 13M 13M 13M 13M 13M 12M 12M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 38M 0 0 0
otherCurrentLiabilities 33M 27M 34M 47M 43M 58M 88M 96M 99M
totalCurrentLiabilities 47M 51M 53M 64M 67M 112M 103M 112M 115M
longTermDebt 85M 89M 93M 91M 83M 100M 102M 96M 100M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 134M 140M 160M 122M 116M 140M 114M 116M 201M
totalNonCurrentLiabilities 220M 228M 253M 213M 199M 240M 216M 212M 217M
otherLiabilities 0 1 0 1 0 0 0 0 0
capitalLeaseObligations 96M 99M 93M 91M 97M 113M 114M 108M 112M
totalLiabilities 267M 279M 306M 278M 266M 352M 319M 323M 332M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 22 000 22 000 22 000 20 000 20 000 20 000 19 000 19 000 19 000
retainedEarnings -1 556M -1 496M -1 446M -1 338M -1 250M -1 251M -1 137M -1 055M -974M
accumulatedOtherComprehensiveIncomeLoss 54 000 -19 000 -15 000 -60 000 -202 000 -865 000 -2M -4M -6M
othertotalStockholdersEquity 1 848M 1 836M 1 821M 1 626M 1 616M 1 607M 1 567M 1 558M 1 547M
totalStockholdersEquity 292M 340M 375M 288M 366M 355M 428M 499M 566M
totalEquity 292M 340M 375M 288M 366M 355M 428M 499M 566M
totalLiabilitiesAndStockholdersEquity 559M 619M 681M 565M 631M 707M 747M 823M 898M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 559M 619M 681M 565M 631M 707M 747M 823M 898M
totalInvestments 72M 117M 134M 72M 100M 152M 195M 257M 348M
totalDebt 96M 99M 106M 104M 97M 113M 114M 108M 112M
netDebt -31M -40M -75M -33M -72M -61M -46M -69M -52M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SANA SANA SANA SANA SANA SANA SANA SANA SANA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-08 2024-08-08 2024-05-08 2023-12-31 2023-11-08 2023-08-03 2023-05-08 2023-03-16 2022-11-02
acceptedDate 2024-11-08 09:14:14 2024-08-08 16:21:48 2024-05-08 16:21:34 2023-12-30 19:00:00 2023-11-08 16:24:11 2023-08-03 16:23:19 2023-05-08 16:33:57 2023-03-16 16:25:20 2022-11-02 16:17:23
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -60M -50M -107M -88M 984 000 -114M -82M -80M -85M
depreciationAndAmortization 4M 4M 4M 8M 4M 4M 4M 4M 4M
deferredIncomeTax 0 0 0 -24M 0 0 0 0 0
stockBasedCompensation 11M 11M 9M 8M 9M 10M 9M 11M 10M
changeInWorkingCapital 5M 2M -7M 10M 5M 14M -11M -6M 12M
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables -507 000 667 000 -1M -1M 2M 441 000 -354 000 -1M 1M
otherWorkingCapital 6M 2M -6M 12M 3M 14M -10M -5M 11M
otherNonCashItems -12M -7M 54M 35M -83M 27M 561 000 -5M -6M
netCashProvidedByOperatingActivities -52M -59M -66M -52M -64M -59M -79M -76M -65M
investmentsInPropertyPlantAndEquipment -4M -13M -16M -14M -2M -2M -2M -5M -4M
acquisitionsNet 0 0 0 -29 356 -53 581 -44 204 0 0 0
purchasesOfInvestments -36M -63M -114M -26M -60M -51M -20M -15M -18M
salesMaturitiesOfInvestments 82M 81M 53M 55M 114M 95M 85M 108M 54M
otherInvestingActivites 0 0 -61M 29 356 53 581 44 204 0 0 0
netCashUsedForInvestingActivites 42M 6M -77M 15M 51M 43M 63M 88M 32M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued -29 000 -439 000 186M 2M 187 000 30M 236 000 -123 000 724 000
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2M 11M 5M 1718 187 0 0 1M 897 000
netCashUsedProvidedByFinancingActivities 2M 11M 186M 2M 187 000 30M 236 000 1M 2M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash -8M -42M 44M -35M -12M 13M -16M 13M -31M
cashAtEndOfPeriod 131M 139M 181M 137M 172M 184M 171M 187M 174M
cashAtBeginningOfPeriod 139M 181M 137M 172M 184M 171M 187M 174M 205M
operatingCashFlow -52M -59M -66M -52M -64M -59M -79M -76M -65M
capitalExpenditure -4M -13M -16M -14M -2M -2M -2M -5M -4M
freeCashFlow -56M -72M -81M -66M -66M -60M -81M -81M -69M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-11-04 21:30 ET
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
2024-10-23 12:00 ET
Flagship Pioneering Announces Appointment of Junaid Bajwa as Senior Partner, Head of United Kingdom, and Science Partner for Pioneering Intelligence
2024-10-03 12:00 ET
Invaio Sciences Appoints André Andonian as Chairman of the Board of Directors
2024-09-30 20:05 ET
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
2024-08-29 20:05 ET
Sana Biotechnology to Present at September 2024 Investor Conferences
2024-08-26 20:05 ET
Sana Biotechnology Appoints Accomplished Drug Developer Dhaval Patel, M.D., Ph.D., as Executive Vice President and Chief Scientific Officer
2024-08-08 20:05 ET
Sana Biotechnology Reports Second Quarter 2024 Financial Results and Business Updates
2024-05-21 13:00 ET
Sana Biotechnology Highlights Publication in Nature Biotechnology of Novel In Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as a Treatment for Huntington’s Disease and Other G...
2024-05-08 20:05 ET
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
2024-05-06 20:05 ET
Sana Biotechnology to Present at May and June 2024 Investor Conferences
2024-02-29 21:05 ET
Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
2024-02-28 21:05 ET
Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference
2024-02-13 21:05 ET
Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP
2024-02-12 21:05 ET
Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2024-02-08 06:22 ET
Sana Biotechnology Announces Pricing of Upsized Public Offering
2024-02-07 21:01 ET
Sana Biotechnology Announces Proposed Public Offering of Common Stock
2024-01-05 14:00 ET
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies
2024-01-03 21:05 ET
Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-11 14:00 ET
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting
2023-12-01 21:05 ET
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
2023-11-21 14:00 ET
Sana Biotechnology to Present at November and December 2023 Investor Conferences
2023-11-21 11:00 ET
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
2023-11-17 14:00 ET
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
2023-11-17 14:00 ET
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
2023-11-09 21:05 ET
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
2023-11-08 21:05 ET
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
2023-11-02 13:05 ET
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
2023-11-01 14:30 ET
Flagship Pioneering Launches Pioneering Intelligence
2023-10-10 20:15 ET
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
2023-09-11 10:30 ET
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer
2023-08-30 20:05 ET
Sana Biotechnology to Present at September 2023 Investor Conferences
2023-08-29 13:00 ET
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
2023-08-03 20:05 ET
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
2023-06-16 13:00 ET
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
2023-05-31 20:05 ET
Sana Biotechnology to Present at June 2023 Investor Conferences
2023-05-16 10:00 ET
Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry
2023-05-08 20:35 ET
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
2023-05-08 20:05 ET
Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates
2023-05-03 20:05 ET
Sana Biotechnology to Present at May 2023 Investor Conferences
2023-05-02 20:30 ET
Sana Biotechnology Announces the Acceptance of Six Abstracts for Presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
2023-04-24 20:05 ET
Sana Biotechnology to Host Research & Development Day
2023-04-19 20:05 ET
Sana Biotechnology Highlights Preclinical Hypoimmune Data for its Allogeneic CAR T Platform and Advancements with its In Vivo Fusogen Platform with Four Presentations at the 2023 AACR Annual Meeting
2023-04-13 13:00 ET
Sana Biotechnology Announces Preclinical Data Published in Nature Communications Demonstrating the Ability of its Hypoimmune Allogeneic CD19-directed CAR T Cells to Evade Immune Rejection and Produce Durable Anti-Tumor Responses
2023-04-12 20:05 ET
Sana Biotechnology Announces Preclinical Data Published in Science Translational Medicine Showing its Hypoimmune Pancreatic Islet Cells Evaded Allogeneic and Autoimmune Rejection and Controlled Type 1 Diabetes in Preclinical Model
2023-04-10 20:05 ET
Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization
2023-03-16 20:05 ET
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
2023-03-14 20:53 ET
Sana Biotechnology Announces the Acceptance of Four Abstracts for Presentation at the 2023 American Association for Cancer Research Annual Meeting
2023-03-01 21:05 ET
Sana Biotechnology to Present at the Cowen 43rd Annual Health Care Conference
2023-02-02 21:05 ET
Sana Biotechnology to Present at the Guggenheim Healthcare Talks 5th Annual Oncology Conference
2023-01-26 21:05 ET
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies
2023-01-03 21:05 ET
Sana Biotechnology to Present at the 41st Annual J.P. Morgan Healthcare Conference
2022-12-11 22:30 ET
Sana Biotechnology Highlights Hypoimmune Allogeneic CAR T Cell Programs and in vivo Technology Platform with Six Presentations at 2022 ASH Annual Meeting
2022-11-29 21:05 ET
Sana Biotechnology Confirms Key Program Timelines and Announces Portfolio Prioritization
2022-11-14 21:05 ET
Sana Biotechnology Tops BioSpace’s 2023 Best Places to Work Ranking in Small Employer Category
2022-11-03 13:07 ET
Sana Biotechnology Announces Several Preclinical Data Presentations at the 64th American Society of Hematology Annual Meeting
2022-11-02 20:05 ET
Sana Biotechnology Reports Third Quarter 2022 Financial Results and Business Updates
2022-09-09 20:05 ET
Sana Biotechnology to Present at September 2022 Investor Conferences
2022-08-04 20:05 ET
Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates
2022-06-17 13:00 ET
Sana Biotechnology Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates
2022-06-13 20:05 ET
Sana Biotechnology Announces Multiple Preclinical Data Presentations to Showcase Its Hypoimmune Platform, Including in Type 1 Diabetes, at the Upcoming ISSCR 2022 Annual Meeting
2022-06-07 20:05 ET
Sana Biotechnology to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
2022-06-01 20:05 ET
Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington Along with Key Executive Hires in Manufacturing and Regulatory
2022-05-12 21:40 ET
Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
2022-05-10 20:05 ET
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
2022-05-04 20:05 ET
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
2022-05-02 20:35 ET
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
2022-03-16 12:30 ET
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
2022-03-09 21:05 ET
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
2022-03-08 21:35 ET
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
2022-01-11 11:00 ET
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
2022-01-10 21:30 ET
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
2022-01-10 21:30 ET
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
2022-01-10 21:30 ET
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
2022-01-04 21:05 ET
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
2021-12-12 14:05 ET
Sana Biotechnology Presentations at 2021 ASH Annual Meeting Highlight Progress with Platforms and CAR T Cell Programs
2021-11-08 21:05 ET
Sana Biotechnology Reports Third Quarter 2021 Financial Results and Business Updates
2021-11-04 13:07 ET
Sana Biotechnology to Present Pre-Clinical Data at 2021 American Society of Hematology Annual Meeting
2021-10-19 13:00 ET
Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
2021-09-07 20:05 ET
Sana Biotechnology to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-09 06:00 ET
MaxCyte Signs Clinical and Commercial License with Sana Biotechnology
2021-08-04 20:05 ET
Sana Biotechnology Reports Second Quarter 2021 Financial Results and Business Updates
2021-07-14 20:10 ET
Sana Biotechnology Enters Long-Term Lease to Establish Manufacturing Facility to Enable Its Gene and Cell Therapy Product Candidates
2021-06-26 14:42 ET
Sana Biotechnology Presents Data at ISSCR 2021 Virtual Annual Meeting Showing Survival of Transplanted Hypoimmune Stem Cells Without Immunosuppression in Non-Human Primates
2021-06-14 13:15 ET
Sana Biotechnology to Present During Plenary Sessions at ISSCR 2021 Virtual Annual Meeting
2021-06-02 20:05 ET
Sana Biotechnology to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
2021-05-05 20:05 ET
Sana Biotechnology Reports First Quarter 2021 Financial Results and Business Updates
2021-05-04 20:05 ET
Sana Biotechnology to Present at the BofA Securities 2021 Healthcare Conference
2021-04-27 20:35 ET
Sana Biotechnology to Present Pre-Clinical Data at American Society of Gene & Cell Therapy Annual Meeting 2021
2021-04-09 13:00 ET
Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
2021-03-24 20:10 ET
Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
2021-03-17 13:00 ET
FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies
2021-02-08 22:23 ET
Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-02-04 04:22 ET
Sana Announces Upsized Pricing of Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2025-05-08 00:00 ET
Sana Biotechnology, Inc. reported for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Sana Biotechnology, Inc. published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Sana Biotechnology, Inc. published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Sana Biotechnology, Inc. published news for 2025 q1
SEC form 8
2025-05-08 00:00 ET
Sana Biotechnology, Inc. published news for 2025 q1
SEC form 10
2025-03-17 20:12 ET
Sana Biotechnology, Inc. reported for 2024 q4
SEC form 8
2025-03-17 20:08 ET
Sana Biotechnology, Inc. published news for 2024 q4
SEC form 8
2025-03-17 20:08 ET
Sana Biotechnology, Inc. published news for 2024 q4
SEC form 10
2025-03-17 00:00 ET
Sana Biotechnology, Inc. reported for 2024 q4
SEC form 10
2024-11-08 09:14 ET
Sana Biotechnology, Inc. reported for 2024 q3
SEC form 8
2024-11-08 09:07 ET
Sana Biotechnology, Inc. published news for 2024 q3
SEC form 8
2024-11-08 09:07 ET
Sana Biotechnology, Inc. published news for 2024 q3
SEC form 10
2024-08-08 16:21 ET
Sana Biotechnology, Inc. reported for 2024 q2
SEC form 8
2024-08-08 16:12 ET
Sana Biotechnology, Inc. published news for 2024 q2
SEC form 8
2024-08-08 16:12 ET
Sana Biotechnology, Inc. published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Sana Biotechnology, Inc. reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Sana Biotechnology, Inc. reported for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Sana Biotechnology, Inc. published news for 2024 q1
SEC form 8
2024-05-08 00:00 ET
Sana Biotechnology, Inc. published news for 2024 q1
SEC form 10
2024-02-29 16:20 ET
Sana Biotechnology, Inc. reported for 2023 q4
SEC form 10
2024-02-29 00:00 ET
Sana Biotechnology, Inc. reported for 2023 q4
SEC form 8
2024-02-29 00:00 ET
Sana Biotechnology, Inc. published news for 2023 q4
SEC form 8
2024-02-29 00:00 ET
Sana Biotechnology, Inc. published news for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Sana Biotechnology, Inc. published news for 2023 q4
SEC form 8
2024-02-07 00:00 ET
Sana Biotechnology, Inc. published news for 2023 q4
SEC form 10
2023-11-08 16:24 ET
Sana Biotechnology, Inc. reported for 2023 q3
SEC form 8
2023-11-08 16:14 ET
Sana Biotechnology, Inc. published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Sana Biotechnology, Inc. reported for 2023 q3
SEC form 10
2023-08-03 16:23 ET
Sana Biotechnology, Inc. reported for 2023 q2
SEC form 6
2023-08-03 16:14 ET
Sana Biotechnology, Inc. reported for 2023 q2
SEC form 10
2023-08-03 00:00 ET
Sana Biotechnology, Inc. reported for 2023 q2
SEC form 8
2023-08-03 00:00 ET
Sana Biotechnology, Inc. reported for 2023 q2
SEC form 6
2023-06-09 16:05 ET
Sana Biotechnology, Inc. published news for 2023 q1
SEC form 6
2023-06-07 06:00 ET
Sana Biotechnology, Inc. published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Sana Biotechnology, Inc. reported for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Sana Biotechnology, Inc. reported for 2023 q1
SEC form 6
2023-04-28 06:11 ET
Sana Biotechnology, Inc. published news for 2023 q1
SEC form 6
2023-04-10 16:15 ET
Sana Biotechnology, Inc. published news for 2023 q1
SEC form 10
2023-03-16 16:25 ET
Sana Biotechnology, Inc. reported for 2022 q4
SEC form 6
2023-03-16 16:15 ET
Sana Biotechnology, Inc. reported for 2022 q4
SEC form 10
2023-03-16 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q4
SEC form 8
2023-03-16 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q4
SEC form 6
2023-01-26 16:16 ET
Sana Biotechnology, Inc. published news for 2022 q4
SEC form 6
2023-01-26 16:16 ET
Sana Biotechnology, Inc. published news for 2022 q4
SEC form 6
2023-01-10 09:01 ET
Sana Biotechnology, Inc. published news for 2022 q4
SEC form 6
2022-11-29 16:11 ET
Sana Biotechnology, Inc. published news for 2022 q3
SEC form 10
2022-11-02 16:17 ET
Sana Biotechnology, Inc. reported for 2022 q3
SEC form 6
2022-11-02 16:11 ET
Sana Biotechnology, Inc. reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q3
SEC form 6
2022-11-01 16:05 ET
Sana Biotechnology, Inc. published news for 2022 q3
SEC form 10
2022-08-04 16:59 ET
Sana Biotechnology, Inc. reported for 2022 q2
SEC form 6
2022-08-04 16:42 ET
Sana Biotechnology, Inc. reported for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q2
SEC form 6
2022-06-14 09:00 ET
Sana Biotechnology, Inc. published news for 2022 q1
SEC form 6
2022-06-09 16:06 ET
Sana Biotechnology, Inc. published news for 2022 q1
SEC form 6
2022-06-01 16:14 ET
Sana Biotechnology, Inc. published news for 2022 q1
SEC form 10
2022-05-10 16:26 ET
Sana Biotechnology, Inc. reported for 2022 q1
SEC form 6
2022-05-10 16:18 ET
Sana Biotechnology, Inc. published news for 2022 q1
SEC form 10
2022-05-10 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q1
SEC form 8
2022-05-10 00:00 ET
Sana Biotechnology, Inc. reported for 2022 q1
SEC form 6
2022-04-26 06:08 ET
Sana Biotechnology, Inc. published news for 2022 q1
SEC form 10
2022-03-16 08:49 ET
Sana Biotechnology, Inc. published news for 2021 q4
SEC form 6
2022-03-16 08:40 ET
Sana Biotechnology, Inc. published news for 2021 q4
SEC form 10
2022-03-16 00:00 ET
Sana Biotechnology, Inc. published news for 2021 q4
SEC form 8
2022-03-16 00:00 ET
Sana Biotechnology, Inc. published news for 2021 q4
SEC form 6
2022-01-11 06:05 ET
Sana Biotechnology, Inc. published news for 2021 q4
SEC form 10
2021-11-08 16:21 ET
Sana Biotechnology, Inc. published news for 2021 q3
SEC form 6
2021-11-08 16:12 ET
Sana Biotechnology, Inc. published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Sana Biotechnology, Inc. published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Sana Biotechnology, Inc. published news for 2021 q3
SEC form 6
2021-10-19 09:10 ET
Sana Biotechnology, Inc. published news for 2021 q3
SEC form 6
2021-09-13 10:01 ET
Sana Biotechnology, Inc. published news for 2021 q2
SEC form 6
2021-09-03 16:10 ET
Sana Biotechnology, Inc. published news for 2021 q2
SEC form 10
2021-08-04 16:31 ET
Sana Biotechnology, Inc. published news for 2021 q2
SEC form 6
2021-08-04 16:23 ET
Sana Biotechnology, Inc. published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
Sana Biotechnology, Inc. published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Sana Biotechnology, Inc. published news for 2021 q2
SEC form 6
2021-07-14 16:15 ET
Sana Biotechnology, Inc. published news for 2021 q2
SEC form 10
2021-05-05 16:40 ET
Sana Biotechnology, Inc. published news for 2021 q1
SEC form 6
2021-05-05 16:19 ET
Sana Biotechnology, Inc. published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
Sana Biotechnology, Inc. published news for 2021 q1
SEC form 10
2021-03-24 16:22 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-03-24 16:19 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-03-02 16:53 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-09 06:01 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:47 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:30 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:30 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:27 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:27 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:23 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:12 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:11 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:10 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:09 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:09 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:07 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 21:06 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 20:10 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 20:09 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 20:03 ET
Sana Biotechnology, Inc. published news for 2020 q4
SEC form 6
2021-02-03 19:59 ET
Sana Biotechnology, Inc. published news for 2020 q4